atcc hp 43 504 strain Search Results


h pylori atcc 43 504  (ATCC)
99
ATCC h pylori atcc 43 504
H Pylori Atcc 43 504, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/h pylori atcc 43 504/product/ATCC
Average 99 stars, based on 1 article reviews
h pylori atcc 43 504 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
helicobacter pylori  (ATCC)
98
ATCC helicobacter pylori
Helicobacter Pylori, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/helicobacter pylori/product/ATCC
Average 98 stars, based on 1 article reviews
helicobacter pylori - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
dm6000b fluorescence 504 microscope  (Danaher Inc)
86
Danaher Inc dm6000b fluorescence 504 microscope
Dm6000b Fluorescence 504 Microscope, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dm6000b fluorescence 504 microscope/product/Danaher Inc
Average 86 stars, based on 1 article reviews
dm6000b fluorescence 504 microscope - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier
pylori atcc 43 504  (ATCC)
93
ATCC pylori atcc 43 504
Pylori Atcc 43 504, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pylori atcc 43 504/product/ATCC
Average 93 stars, based on 1 article reviews
pylori atcc 43 504 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
pylori  (ATCC)
95
ATCC pylori
Pylori, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pylori/product/ATCC
Average 95 stars, based on 1 article reviews
pylori - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
sglt2i  (TriNetX Inc)
90
TriNetX Inc sglt2i
Characteristics of the included studies
Sglt2i, supplied by TriNetX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sglt2i/product/TriNetX Inc
Average 90 stars, based on 1 article reviews
sglt2i - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
h pylori atcc 43 504 stander  (ATCC)
92
ATCC h pylori atcc 43 504 stander
Inhibition zone diameter (mm) of Cur-CLR-NE, Curcumin, and clarithromycin against <t> H. pylori </t> isolate and stander strains
H Pylori Atcc 43 504 Stander, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/h pylori atcc 43 504 stander/product/ATCC
Average 92 stars, based on 1 article reviews
h pylori atcc 43 504 stander - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
viszeralchirurgie  (Georg Thieme Verlag KG)
90
Georg Thieme Verlag KG viszeralchirurgie
Inhibition zone diameter (mm) of Cur-CLR-NE, Curcumin, and clarithromycin against <t> H. pylori </t> isolate and stander strains
Viszeralchirurgie, supplied by Georg Thieme Verlag KG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/viszeralchirurgie/product/Georg Thieme Verlag KG
Average 90 stars, based on 1 article reviews
viszeralchirurgie - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
novellie- bundesgesundheitsbl - gesundheitsforsch - gesundheitsschutz  (Verlag GmbH)
90
Verlag GmbH novellie- bundesgesundheitsbl - gesundheitsforsch - gesundheitsschutz
Inhibition zone diameter (mm) of Cur-CLR-NE, Curcumin, and clarithromycin against <t> H. pylori </t> isolate and stander strains
Novellie Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/novellie- bundesgesundheitsbl - gesundheitsforsch - gesundheitsschutz/product/Verlag GmbH
Average 90 stars, based on 1 article reviews
novellie- bundesgesundheitsbl - gesundheitsforsch - gesundheitsschutz - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
strains nctc 11 638  (ATCC)
94
ATCC strains nctc 11 638
Inhibition zone diameter (mm) of Cur-CLR-NE, Curcumin, and clarithromycin against <t> H. pylori </t> isolate and stander strains
Strains Nctc 11 638, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/strains nctc 11 638/product/ATCC
Average 94 stars, based on 1 article reviews
strains nctc 11 638 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
z-coriolis hlj  (Coriolis Pharma)
90
Coriolis Pharma z-coriolis hlj
Inhibition zone diameter (mm) of Cur-CLR-NE, Curcumin, and clarithromycin against <t> H. pylori </t> isolate and stander strains
Z Coriolis Hlj, supplied by Coriolis Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/z-coriolis hlj/product/Coriolis Pharma
Average 90 stars, based on 1 article reviews
z-coriolis hlj - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Characteristics of the included studies

Journal: Cardiovascular Diabetology

Article Title: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

doi: 10.1186/s12933-024-02192-4

Figure Lengend Snippet: Characteristics of the included studies

Article Snippet: Riley et al. [ ] , Global , 2.2 million , SGLT2i (n = 1,43,600) GLP-1RA (n = 1,86,841) SGLT2i + GLP-1RA (n = 1,08,504) , 5 years , Retrospective, observational cohort study based on inpatient and outpatient electronic medical records from TriNetX , Y.

Techniques:

Characteristics of participants in the included studies

Journal: Cardiovascular Diabetology

Article Title: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

doi: 10.1186/s12933-024-02192-4

Figure Lengend Snippet: Characteristics of participants in the included studies

Article Snippet: Riley et al. [ ] , Global , 2.2 million , SGLT2i (n = 1,43,600) GLP-1RA (n = 1,86,841) SGLT2i + GLP-1RA (n = 1,08,504) , 5 years , Retrospective, observational cohort study based on inpatient and outpatient electronic medical records from TriNetX , Y.

Techniques:

Antidiabetic drugs used by patients in the included studies

Journal: Cardiovascular Diabetology

Article Title: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

doi: 10.1186/s12933-024-02192-4

Figure Lengend Snippet: Antidiabetic drugs used by patients in the included studies

Article Snippet: Riley et al. [ ] , Global , 2.2 million , SGLT2i (n = 1,43,600) GLP-1RA (n = 1,86,841) SGLT2i + GLP-1RA (n = 1,08,504) , 5 years , Retrospective, observational cohort study based on inpatient and outpatient electronic medical records from TriNetX , Y.

Techniques: Medications

Findings from the main analysis. A Odds of all-cause mortality with SGLT2i + GLP-1RA combination therapy versus SGLT2i or GLP-1RA therapy. B Changes in BMI with combination therapy at the baseline versus the 6-month follow-up. C Changes in SBP with combination therapy at the baseline versus the 6-month follow-up. D Changes in total cholesterol with combination therapy at the baseline versus the 6-month follow-up. E Changes in eGFR with simultaneous combination therapy at the baseline versus the 6-month follow-up. F Changes in HbA1c with combination therapy at the baseline versus the 6-month follow-up. G Changes in FPG with combination therapy at the baseline versus the 6-month follow-up. BMI Body mass index, CI confidence interval, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, M–H Mantel–Haenszel, GLP-1RA glucagon-like peptide-1 receptor agonist, HbA1c glycated hemoglobin, IV importance value, SBP systolic blood pressure, SD standard deviation, SGLT2i Sodium–glucose transport protein 2 inhibitor

Journal: Cardiovascular Diabetology

Article Title: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

doi: 10.1186/s12933-024-02192-4

Figure Lengend Snippet: Findings from the main analysis. A Odds of all-cause mortality with SGLT2i + GLP-1RA combination therapy versus SGLT2i or GLP-1RA therapy. B Changes in BMI with combination therapy at the baseline versus the 6-month follow-up. C Changes in SBP with combination therapy at the baseline versus the 6-month follow-up. D Changes in total cholesterol with combination therapy at the baseline versus the 6-month follow-up. E Changes in eGFR with simultaneous combination therapy at the baseline versus the 6-month follow-up. F Changes in HbA1c with combination therapy at the baseline versus the 6-month follow-up. G Changes in FPG with combination therapy at the baseline versus the 6-month follow-up. BMI Body mass index, CI confidence interval, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, M–H Mantel–Haenszel, GLP-1RA glucagon-like peptide-1 receptor agonist, HbA1c glycated hemoglobin, IV importance value, SBP systolic blood pressure, SD standard deviation, SGLT2i Sodium–glucose transport protein 2 inhibitor

Article Snippet: Riley et al. [ ] , Global , 2.2 million , SGLT2i (n = 1,43,600) GLP-1RA (n = 1,86,841) SGLT2i + GLP-1RA (n = 1,08,504) , 5 years , Retrospective, observational cohort study based on inpatient and outpatient electronic medical records from TriNetX , Y.

Techniques: Filtration, Clinical Proteomics, Standard Deviation

Findings from the subgroup analyses. A Changes in BMI with simultaneous versus sequential combination therapy at the 6-month follow-up. B Changes in SBP with simultaneous versus sequential combination therapy at the 6-month follow-up. C Changes in HbA1c levels with simultaneous versus sequential combination therapy at the 6-month follow-up. D Changes in FPG levels with simultaneous versus sequential combination therapy at the 6-month follow-up. BMI body mass index, CI confidence interval, FPG fasting plasma glucose, GLP-1RA glucagon-like peptide-1 receptor agonist, HbA1c glycated hemoglobin, IV importance value, SBP systolic blood pressure, SD standard deviation, SGLT2i sodium–glucose transport protein 2 inhibitor, Seq. Combn. Tx sequential combination therapy, Simult. Combn. Tx simultaneous combination therapy

Journal: Cardiovascular Diabetology

Article Title: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

doi: 10.1186/s12933-024-02192-4

Figure Lengend Snippet: Findings from the subgroup analyses. A Changes in BMI with simultaneous versus sequential combination therapy at the 6-month follow-up. B Changes in SBP with simultaneous versus sequential combination therapy at the 6-month follow-up. C Changes in HbA1c levels with simultaneous versus sequential combination therapy at the 6-month follow-up. D Changes in FPG levels with simultaneous versus sequential combination therapy at the 6-month follow-up. BMI body mass index, CI confidence interval, FPG fasting plasma glucose, GLP-1RA glucagon-like peptide-1 receptor agonist, HbA1c glycated hemoglobin, IV importance value, SBP systolic blood pressure, SD standard deviation, SGLT2i sodium–glucose transport protein 2 inhibitor, Seq. Combn. Tx sequential combination therapy, Simult. Combn. Tx simultaneous combination therapy

Article Snippet: Riley et al. [ ] , Global , 2.2 million , SGLT2i (n = 1,43,600) GLP-1RA (n = 1,86,841) SGLT2i + GLP-1RA (n = 1,08,504) , 5 years , Retrospective, observational cohort study based on inpatient and outpatient electronic medical records from TriNetX , Y.

Techniques: Clinical Proteomics, Standard Deviation

Findings of the GRADE analysis

Journal: Cardiovascular Diabetology

Article Title: Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

doi: 10.1186/s12933-024-02192-4

Figure Lengend Snippet: Findings of the GRADE analysis

Article Snippet: Riley et al. [ ] , Global , 2.2 million , SGLT2i (n = 1,43,600) GLP-1RA (n = 1,86,841) SGLT2i + GLP-1RA (n = 1,08,504) , 5 years , Retrospective, observational cohort study based on inpatient and outpatient electronic medical records from TriNetX , Y.

Techniques: Comparison

Inhibition zone diameter (mm) of Cur-CLR-NE, Curcumin, and clarithromycin against H. pylori isolate and stander strains

Journal: World Journal of Microbiology & Biotechnology

Article Title: Curcumin clarithromycin nano-form a promising agent to fight Helicobacter pylori infections

doi: 10.1007/s11274-023-03745-7

Figure Lengend Snippet: Inhibition zone diameter (mm) of Cur-CLR-NE, Curcumin, and clarithromycin against H. pylori isolate and stander strains

Article Snippet: H. pylori ATCC 43,504 (stander) , 100 , 50 , 12.5.

Techniques: Inhibition

Minimum inhibitory concentration of Curcumin Clarithromycin Nano-Emulsion against H. pylori

Journal: World Journal of Microbiology & Biotechnology

Article Title: Curcumin clarithromycin nano-form a promising agent to fight Helicobacter pylori infections

doi: 10.1007/s11274-023-03745-7

Figure Lengend Snippet: Minimum inhibitory concentration of Curcumin Clarithromycin Nano-Emulsion against H. pylori

Article Snippet: H. pylori ATCC 43,504 (stander) , 100 , 50 , 12.5.

Techniques: Concentration Assay